Clinical Genomics to Drug Discovery Using Machine Learning for Neurodegenerative Disorders: A Future Perspective

Neurodegenerative diseases affect the central nervous system and lead to death of neuronal cells. Development of therapeutics for neurodegenerative diseases is more challenging as compared to other diseases. Exploring the association of neurodegenerative diseases with human gut microbiome can lead to development of microbiome-based therapeutics. Advancement in tools and techniques has changed the face of traditional clinical genomics. Integration of omics approach with computer-aided drug discovery and artificial intelligence gives a multi-dimensional insight into diagnosis and prognosis of neurodegenerative diseases. Faecal samples of patients of neurodegenerative diseases can be analysed using Next Generation Sequencing approach and can be further integrate with drug discovery approach to get insight into the important genes of highly abundant microbes in human gut. Furthermore, Magnetic Resonance Imaging (MRI), Single-photon emission computed tomography (SPECT), and positron emission tomography (PET) of patients can be analysed using various Artificial Intelligence approach to develop models for prediction and analysis of the neurodegenerative disease as well as classification of diseases.